ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments (2023 - 2026)

ARS Pharmaceuticals has reported Change in Acquisitions & Divestments for 4 years, with the latest figure at $42.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 33.07% year-over-year to $42.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $286.0 million (up 7.32% YoY) and the FY2025 annual result came in at $307.0 million, up 18.99% from the prior year.
• Change in Acquisitions & Divestments declined to $42.5 million in Q1 2026 per SPRY's latest filing, from $75.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $88.5 million in Q3 2025 and troughed at $20.0 million in Q1 2023.
• A 4-year average of $61.0 million and a median of $61.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2024 and 2026: Change in Acquisitions & Divestments surged 175.0% in 2024, then tumbled 33.07% in 2026.
• Over 4 years, Change in Acquisitions & Divestments stood at $60.0 million in 2023, then gained by 11.67% to $67.0 million in 2024, then climbed by 11.94% to $75.0 million in 2025, then plunged by 43.33% to $42.5 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $42.5 million, $75.0 million, and $88.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.